Filing Flows › United Therapeutics (UTHR) › Orenitram revenue
United Therapeutics (UTHR) Orenitram revenue by quarter
United Therapeutics' Orenitram revenue was $145M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 7 quarters it ranged from $121M (Q1 2025) to $145M (Q3 2026).
| Quarter | Orenitram revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $145M | +15% | +11% |
| Q2 2026 | $126M | -7% | +1% |
| Q1 2026 | $136M | +12% | +12% |
| Q4 2025 | $121M | -8% | — |
| Q3 2025 | $131M | +6% | — |
| Q2 2025 | $124M | +3% | — |
| Q1 2025 | $121M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' Orenitram revenue?
United Therapeutics' Orenitram revenue was $145M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has United Therapeutics' Orenitram revenue changed?
Over the last 7 quarters it ranged from $121M (Q1 2025) to $145M (Q3 2026).